News Sentiment

ONC sentiment intelligence

BeiGene, Ltd. news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 58 Balanced news tone 20 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 312.02 Week of 17 Jul 2026
Weighted tone 58/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Analyst action

76/100 classification confidence.

Company focus 11

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

+4.5% over one week, +15.5% over four weeks, trend inactive, and materially above fair value.

Latest direct headline Positive

BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC) Given Consensus Rating of "Moderate Buy" by Brokerages

Market Reaction

Price moving ahead of tone

66/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Analyst action 76/100 classification
One-week reaction 4.5% Price confirming higher
Trend fit Trend inactive 15.5% over four weeks
Fair value 32.7% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 8
Neutral 10
Negative 2

Relevance

Why the article matched

Direct first
Direct company coverage 11
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Moomoo 7
Market source 6
MarketBeat 4
simplywall.st 2
TradingView 1

Event Lens

What the news is about

Classified themes
Earnings 9
Analyst action 8
Market update 3

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-20 of 20
Moomoo Direct company coverage

BeiGene(ONC.US) Officer Sells US$62.88 Million in Common Stock

An officer at BeiGene (ONC.US) executed a sale of common stock totaling US$62.88 million. This transaction indicates a significant insider selling activity, which can be of interest to investors monitoring corporate governance and stock performance.

Tone
Negative 29/100
Event
Market update
Published
15 Jul 2026 03:41
Source
Moomoo
Moomoo Direct company coverage

Jefferies Upgrades BeiGene(ONC.US) to Buy Rating, Raises Target Price to $380

Jefferies has upgraded BeiGene (ONC.US) from a Hold to a Buy rating, concurrently increasing its target price to $380. This positive revision reflects a strong outlook for the biotechnology company.

Tone
Positive 71/100
Event
Analyst action
Published
13 Jul 2026 08:40
Source
Moomoo
Moomoo Direct company coverage

RBC Capital Maintains BeiGene(ONC.US) With Buy Rating, Raises Target Price to $451

RBC Capital analyst Leonid Timashev has maintained a Buy rating for BeiGene (ONC.US) and increased the target price from $436 to $451. The analyst has a notable success rate of 62.0% and an average return of 26.8% over the past year, according to TipRanks data. This adjustment re

Tone
Positive 71/100
Event
Analyst action
Published
07 Jul 2026 14:40
Source
Moomoo
Moomoo Direct company coverage

Wolfe Research Maintains BeiGene(ONC.US) With Buy Rating, Maintains Target Price $340

Wolfe Research has reiterated its Buy rating on BeiGene (BGNE.US) and maintained its target price of $340. The report reflects the firm's continued confidence in the pharmaceutical company's performance and future outlook.

Tone
Positive 71/100
Event
Analyst action
Published
02 Jul 2026 12:39
Source
Moomoo
Moomoo Direct company coverage

Barclays Maintains BeiGene(ONC.US) With Buy Rating, Maintains Target Price $409

Barclays has reiterated its Buy rating on BeiGene (ONC.US) and maintained a target price of $409. This continued endorsement suggests confidence in the company's future performance. The financial institution's updated rating provides insight into its current outlook on BeiGene's

Tone
Positive 76/100
Event
Analyst action
Published
16 Jun 2026 12:10
Source
Moomoo
Moomoo Direct company coverage

Guggenheim Maintains BeiGene(ONC.US) With Buy Rating, Maintains Target Price $420

Guggenheim has reiterated its Buy rating on BeiGene (ONC.US), maintaining a target price of $420. This indicates the firm's continued confidence in the pharmaceutical company's stock performance and future prospects.

Tone
Positive 71/100
Event
Analyst action
Published
15 Jun 2026 23:39
Source
Moomoo